Voya Global Advantage & Premium Opportunity Fund IGA 深沪

等待开盘 10-09 09:30:00 美东时间

9.9325

+0.083

+0.84%

华盛通

立即下载

最高10.02
今开9.91
成交量 7.22万股
最低 9.87
昨收 9.85
总市值 1.52亿
52周最高 10.02
市盈率 ^静 6.62
换手率 0.47%
52周最低 7.92
委比 -90.48%
总股本 1534.14万
历史最高 10.02
量比 1.01
振幅 1.52%
历史最低 1.121
每手 1
风险率 0.50%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

Escalade Announces Acquisition of Gold Tip, a Leading Archery Brand, from Revelyst

EVANSVILLE, Ind. and PROVIDENCE, R.I., Sept. 29, 2025 /PRNewswire/ -- Escalade, Inc. (NASDAQ: ESCA), a leader in archery, sporting goods and indoor/outdoor recreation equipment, today announ...

09-29 18:00
重磅！阿斯利康达格列净大幅降价70%

达格列净片，由百时美施贵宝开发，是全球首款获批上市的SGLT-2（钠－葡萄糖协同转运蛋白-2）抑制剂，后全球销售权被阿斯利康收购。达格列净片最早于2012年...

09-29 11:24
AstraZeneca Rolls Out AstraZeneca Direct Platform For Patients To Access Prescribed Medicines With Home Delivery

AstraZeneca Direct is designed to offer greater convenienceAstraZeneca today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access

09-26 21:13
Why Is Nektar Therapeutics Stock Trading Lower On Thursday?

Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.

09-19 02:31
Nektar Therapeutics Announces New Data From Ongoing REZOLVE-AD Phase 2b Study Of Rezpegaldesleukin At 2025 EADV Congress

Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitisHigh dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments

09-18 20:47
国金医药甘坛焕丨特应性皮炎专题研究：掘金百亿AD蓝海，现有疗法仍可优化，双抗药物有望破局

（来源：国金证券研究所）　　作者：甘坛焕、唐玉青摘要　　特应性皮炎以瘙痒作为重要标志，患者人群众多，疾病负担较重。特应性皮炎（AD）是一种慢性、复发性...

09-17 07:33
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in moderate to severe atopic dermatitis patients.

09-10 03:06
赛诺菲重磅单抗三期临床成功，但股价为何下跌120亿美元？

（来源：医趋势） 9月4日盘前，赛诺菲股价下跌10%，市值跌去120亿美元。主要原因在于，其实验性炎症药物Amlitelimab在后期临床试验中的疗...

09-08 14:16
III期临床赢了，股价却暴跌？赛诺菲OX40的魔幻时刻

（来源：求实药社）又一项针对自免炎症的单抗三期临床成功了。赛诺菲今日宣布消息，其靶向OX40L（OX40配体）的全人源非T细胞耗竭性单克隆抗体——Amlit...

09-05 11:46
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.

09-04 21:21

派息除权日	每股总股息	派息日期
2025-10-01	0.09	2025-10-15
2025-09-02	0.09	2025-09-15
2025-08-04	0.09	2025-08-15
2025-08-01	0.09	2025-08-15
2025-07-01	0.09	2025-07-15
2025-06-02	0.09	2025-06-16
2025-05-01	0.09	2025-05-15
2025-04-01	0.09	2025-04-15
2025-03-03	0.09	2025-03-17
2025-02-03	0.09	2025-02-18
2024-12-30	0.09	2025-01-15
2024-12-02	0.09	2024-12-16
2024-11-01	0.09	2024-11-15
2024-10-01	0.09	2024-10-15
2024-09-04	0.09	2024-09-16
2024-09-03	0.09	2024-09-16
2024-08-01	0.09	2024-08-15
2024-07-01	0.09	2024-07-15
2024-06-03	0.09	2024-06-17
2024-05-01	0.09	2024-05-15
2024-04-01	0.20	2024-04-15
2023-12-28	0.20	2024-01-16
2023-10-02	0.20	2023-10-16
2023-07-03	0.20	2023-07-17
2023-04-03	0.20	2023-04-17
2022-12-29	0.20	2023-01-17
2022-10-03	0.20	2022-10-17
2022-07-01	0.20	2022-07-15
2022-04-01	0.20	2022-04-18
2021-12-30	0.20	2022-01-18
2021-10-01	0.20	2021-10-15
2021-07-01	0.20	2021-07-15
2021-04-01	0.20	2021-04-15
2020-12-30	0.20	2021-01-15
2020-10-01	0.20	2020-10-15
2020-07-01	0.20	2020-07-15
2020-04-01	0.20	2020-04-15
2019-12-30	0.20	2020-01-15
2019-10-01	0.20	2019-10-15
2019-07-01	0.22	2019-07-15
2019-04-01	0.22	2019-04-15
2018-12-28	0.22	2019-01-15
2018-10-01	0.22	2018-10-15
2018-07-02	0.22	2018-07-16
2018-04-02	0.22	2018-04-16
2017-12-28	0.22	2018-01-16
2017-10-03	0.22	2017-10-16
2017-07-03	0.22	2017-07-17
2017-04-03	0.22	2017-04-17
2016-12-28	0.22	2017-01-17
2016-10-03	0.28	2016-10-17
2016-07-01	0.28	2016-07-15
2016-04-01	0.28	2016-04-15
2015-12-29	0.28	2016-01-15
2015-10-01	0.28	2015-10-15
2015-07-01	0.28	2015-07-15
2015-04-01	0.28	2015-04-15
2014-12-29	0.28	2015-01-15
2014-10-01	0.28	2014-10-15
2014-07-01	0.28	2014-07-15
2014-04-01	0.28	2014-04-15
2013-12-27	0.28	2014-01-15
2013-10-01	0.28	2013-10-15
2013-07-01	0.28	2013-07-15
2013-04-01	0.28	2013-04-15
2012-12-27	0.28	2013-01-15
2012-10-01	0.28	2012-10-15
2012-07-02	0.31	2012-07-16
2012-04-02	0.31	2012-04-16
2011-12-28	0.31	2012-01-16
2011-10-03	0.34	2011-10-17
2011-07-01	0.34	2011-07-15
2011-04-01	0.34	2011-04-15
2010-12-29	0.34	2011-01-17
2010-10-01	0.34	2010-10-15
2010-07-01	0.34	2010-07-15
2010-04-01	0.37	2010-04-15
2009-12-29	0.37	2010-01-15
2009-10-01	0.47	2009-10-15
2009-06-30	0.47	2009-07-15
2009-04-01	0.47	2009-04-15
2008-12-29	0.47	2009-01-15
2008-10-01	0.47	2008-10-15
2008-07-01	0.47	2008-07-15
2008-04-01	0.47	2008-04-15
2007-12-27	1.58	2008-01-15
2007-10-01	0.47	2007-10-15
2007-07-02	0.47	2007-07-16
2007-04-02	0.47	2007-04-16
2006-12-27	0.47	2007-01-16
2006-10-02	0.47	2006-10-16
2006-07-03	0.47	2006-07-17
2006-03-29	0.47	2006-04-17
2005-12-28	0.16	2006-01-15

公司名称	Voya Global Advantage & Premium Opportunity Fund
行业分类	--
业务描述	Voya Global Advantage & Premium Opportunity Fund operates as closed-end investment fund. Its portfolio includes current income, capital gains, and appreciation through equity security investment in Asia Pacific companies. The company was founded on October 26, 2005 and is headquartered in Scottsdale, AZ.

Voya Global Advantage & Premium Opportunity Fund IGA 深 沪

9.9325

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

Voya Global Advantage & Premium Opportunity Fund IGA 深沪